Latest Meningococcal disease Stories
A study of 4CMenB, a new vaccine to protect against meningitis B bacteria (which can cause potentially fatal bacterial meningitis in children), shows that waning immunity induced by infant vaccination can be overcome by a booster dose at 40 months of age.
Evaluation of the effectiveness of a mass vaccination campaign with a new meningitis serogroup A vaccine, PsA-TT, in sub-Saharan Africa found that it had a dramatic impact on cases of serogroup meningitis and on carriage of the disease-causing bacteria in the throat.
RnRMarketResearch.com adds Latest Report on “EpiCast Report: Meningococcal Disease – Epidemiology Forecast to 2022” to its store. Dallas, Texas (PRWEB)
In a study that included nearly 3,000 adults from Denmark, a diagnosis of meningococcal, pneumococcal, or Haemophilus influenzae meningitis in childhood was associated with lower educational achievement and economic self-sufficiency in adult life.
This study is a Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial to Assess the Safety, Tolerability and Immunogenicity of a new Meningococcal Vaccine When Given in Healthy Subjects
Neisseria meningitidis is a heterotrophic gram-negative diplococcal bacterium best known for its role in meningitis and other forms of meningococcal disease such as meningococcemia. It is a major cause of morbidity and mortality during childhood in industrialized countries and is responsible for epidemics in Africa and in Asia. In the US there are approximately 2500 to 3500 cases of N. meningitides infections. Children under 5 are at a higher risk as well as people in the sub-Saharan...
- An armed gangster.